Streetbeat News

Price Targets

ARES

Wells Fargo analyst Timothy O'Shea downgrades Ares Management (NYSE:ARES) from Overweight to Equal-Weight and lowers the price target from $99 to $93.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:39 am

FND

Evercore ISI Group analyst Greg Melich downgraded Floor & Decor Holdings (NYSE:FND) from Outperform to In-Line and announced a $95 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:37 am

AZO

Evercore ISI Group analyst Greg Melich has upgraded AutoZone (NYSE:AZO) from In-Line to Outperform and set a new price target of $2700.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:35 am

CNP

Guggenheim analyst Shahriar Pourreza upgraded CenterPoint Energy (NYSE:CNP) from Neutral to Buy and announced a $32 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:33 am

RETA

SVB Leerink analyst Joseph Schwartz upgraded Reata Pharmaceuticals (NASDAQ:RETA) from Market Perform to Outperform and raised the price target from $80 to $115.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:32 am

CFLT

Needham analyst Mike Cikos maintains a Buy rating on Confluent (NASDAQ:CFLT) and raises the price target from $35 to $45.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:30 am

FN

Needham analyst Alex Henderson maintains a Buy rating on Fabrinet (NYSE:FN) and raises the price target from $120 to $150.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:29 am

USGO

HC Wainwright & Co. analyst Heiko Ihle initiates coverage on US Goldmining (NASDAQ:USGO) with a Buy rating and announces a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:18 am

CLDX

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and maintains a $73 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:18 am

PTGX

HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) and maintains a $38 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 10:17 am